ProPhase Labs, Inc.
Price data unavailable
Track PRPH in your trading journalAbout ProPhase Labs, Inc.
ProPhase Labs, Inc. (PRPH) is a publicly listed company on US equity markets.
PROPHASE LABS INC
The company reports trailing twelve-month revenue of $24.20M and net loss of $6.84M.
Key metrics include a return on equity of -99.7%, a debt-to-equity ratio of 8.58.
Use FINOTAUR to track PRPH's price action, review fundamentals, and stay current with company news — all in one research dashboard.
Fundamentals
| Revenue (TTM) | $24.20M |
| Net Income (TTM) | $-6.84M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | -99.68% |
| Debt-to-Equity | 8.58 |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·Jan 5
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
- The Motley Fool·Aug 13
ProPhase Labs Posts Narrower Q2 Loss
- GlobeNewswire Inc.·Jun 6
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
Want real-time analysis on PRPH?
Track it free in your trading journal. Log trades, tag setups, and review your edge.